| +0.13 / +2.15%|
The 8 analysts offering 12-month price forecasts for Endocyte Inc have a median target of 11.25, with a high estimate of 26.00 and a low estimate of 7.00. The median estimate represents a +82.04% increase from the last price of 6.18.
The current consensus among 9 polled investment analysts is to Buy stock in Endocyte Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.